Posts

KOL Bulletin - FDA Approves Revtorpyk for HR+ / HER2– Metastatic Breast Cancer, but Logistical Hurdles May Restrict Uptake

on

Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

on

Friday Five: Freenome's CRC Test Wins FDA Nod

on

AbbVie scores dual EU approvals for Rinvoq in vitiligo, alopecia

on

AbbVie Scores First Rinvoq Alopecia Nod in EU

on

MannKind Receives FDA Approval for Furoscix ReadyFlow Autoinjector for Edema in Heart Failure and CKD

on

Apnimed Targets Up to $160M IPO for Sleep Apnea Drug Oxnimbi Launch

on

FDA Approves Otsuka's Tool SIMTRIYO

on

AZ wins EU nod for camizestrant

on

Summit reports two‑year survival data for Western patients, though context lacking

on

Nuvalent's cancer drug under FDA review, weeks after GSK closes $10.6B buyout

on

Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill

on

Sanofi's Sarclisa Goes Hands-Free: Will It Matter to Physicians?

on

Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA

on

Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

on

GSK readies global submissions for Jemperli in dMMR/MSI-H rectal cancer

on

Celcuity Wins FDA Approval for First-in-Class Breast Cancer Drug Revtorpyk (gedatolisib)

on

Eisai, Biogen scoop up subQ Leqembi starter‑dose nod – FDA greenlights subcutaneous lecanemab initiation for early Alzheimer’s disease

on

AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B

on

GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win

on